Naturally upregulated by the induction of estrogen, circPGR aggravates breast cancer progression by suppressing its target, miR-301a-5p, which partially binds to CDK1, CDK6, and checkpoint kinase 2 (CHEK2) mRNA. Here, CHEK2 is linked to breast carcinoma.